NO20054404L - 5,7-Diaminopyrazolo [4,3-D] Pyrimidiner Anvendelige ved behandling av of Hypertensjon - Google Patents

5,7-Diaminopyrazolo [4,3-D] Pyrimidiner Anvendelige ved behandling av of Hypertensjon

Info

Publication number
NO20054404L
NO20054404L NO20054404A NO20054404A NO20054404L NO 20054404 L NO20054404 L NO 20054404L NO 20054404 A NO20054404 A NO 20054404A NO 20054404 A NO20054404 A NO 20054404A NO 20054404 L NO20054404 L NO 20054404L
Authority
NO
Norway
Prior art keywords
diaminopyrazolo
hypertension
treatment
pyrimidines useful
pyrimidines
Prior art date
Application number
NO20054404A
Other languages
English (en)
Other versions
NO333850B1 (no
NO20054404D0 (no
Inventor
David Nathan Abraham Fox
Andrew Ian Morrell
Michael John Palmer
Andrew Simon Bell
David Graham Brown
Ian Roger Marsh
Carol Ann Winslow
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0327748.0A external-priority patent/GB0327748D0/en
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of NO20054404D0 publication Critical patent/NO20054404D0/no
Publication of NO20054404L publication Critical patent/NO20054404L/no
Publication of NO333850B1 publication Critical patent/NO333850B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

Foreliggende oppfinnelse angår forbindelser med formel (I).
NO20054404A 2003-04-29 2005-09-22 5,7-Diaminopyrazolo[4,3-D]pyrimidiner anvendelige ved behandling av hypertensjon NO333850B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0309780 2003-04-29
GBGB0327748.0A GB0327748D0 (en) 2003-11-28 2003-11-28 Novel pharmaceuticals
PCT/IB2004/001433 WO2004096810A1 (en) 2003-04-29 2004-04-22 5,7-diaminopyrazolo`4,3-d!pyrimidines useful in the treatment of hypertension

Publications (3)

Publication Number Publication Date
NO20054404D0 NO20054404D0 (no) 2005-09-22
NO20054404L true NO20054404L (no) 2005-11-24
NO333850B1 NO333850B1 (no) 2013-09-30

Family

ID=33420887

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054404A NO333850B1 (no) 2003-04-29 2005-09-22 5,7-Diaminopyrazolo[4,3-D]pyrimidiner anvendelige ved behandling av hypertensjon

Country Status (32)

Country Link
US (2) US7262192B2 (no)
EP (1) EP1620437B1 (no)
JP (2) JP4015176B2 (no)
KR (1) KR100824193B1 (no)
AR (1) AR044116A1 (no)
AT (1) ATE433978T1 (no)
AU (1) AU2004234158B2 (no)
BR (1) BRPI0409903A (no)
CA (1) CA2523831C (no)
CL (1) CL2004000889A1 (no)
CO (1) CO5640118A2 (no)
CR (1) CR8051A (no)
DE (1) DE602004021585D1 (no)
DK (1) DK1620437T3 (no)
EA (1) EA008596B1 (no)
EC (1) ECSP056130A (no)
ES (1) ES2326119T3 (no)
GE (1) GEP20084329B (no)
HK (1) HK1087108A1 (no)
IS (1) IS8009A (no)
MA (1) MA27771A1 (no)
MX (1) MXPA05011643A (no)
NL (1) NL1026074C2 (no)
NO (1) NO333850B1 (no)
NZ (1) NZ542097A (no)
OA (1) OA13050A (no)
PA (1) PA8601701A1 (no)
PE (1) PE20050462A1 (no)
RS (1) RS20050810A (no)
TW (1) TWI273908B (no)
UY (1) UY28290A1 (no)
WO (1) WO2004096810A1 (no)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096810A1 (en) 2003-04-29 2004-11-11 Pfizer Limited 5,7-diaminopyrazolo`4,3-d!pyrimidines useful in the treatment of hypertension
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
GB0327319D0 (en) * 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
GB0327323D0 (en) * 2003-11-24 2003-12-31 Pfizer Ltd Novel pharmaceuticals
WO2005097799A1 (en) 2004-04-07 2005-10-20 Pfizer Limited Pyrazolo`4,3-d! pyrimidines
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
CN101084212A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶介导剂的用途
EP2289510A1 (en) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
US7592343B2 (en) 2004-09-20 2009-09-22 Xenon Pharmaceuticals Inc. Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors
MX2007003321A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
CN101084207A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
WO2006034440A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CA2585557C (en) * 2004-10-28 2009-08-18 Pharmacia & Upjohn Company Llc Pyrazolo[4,3-d] pyrimidine derivatives useful as pde-5 inhibitors
GB0428250D0 (en) * 2004-12-23 2005-01-26 Novartis Ag Organic compounds
EP1831216A2 (en) * 2004-12-23 2007-09-12 Pfizer Products Inc. Heteroaromatic derivatives useful as anticancer agents
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
WO2006115452A1 (en) * 2005-04-27 2006-11-02 Astrazeneca Ab Use of pyrazolyl-pyrimidine derivatives in the treatment of pain
ES2357120T3 (es) * 2005-05-12 2011-04-18 Pfizer, Inc. Formas cristalinas anhidra de n-(1-(2-etoxietil)-5-(n-etil-n-metilamino)-7-(4-metilpiridin-2-il-amino)-1h-pirazolo(4,3-d)pirimidina-3-carbonil)metanosulfonamida.
US8227475B2 (en) 2005-05-12 2012-07-24 Pfizer Inc. Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
CN101208089A (zh) 2005-06-03 2008-06-25 泽农医药公司 氨基噻唑衍生物作为人硬酯酰-CoA去饱和酶抑制剂
US7932257B2 (en) 2005-07-22 2011-04-26 Sunesis Pharmaceuticals, Inc. Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase inhibitors
WO2007023382A2 (en) * 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
NL2000291C2 (nl) 2005-11-10 2009-02-17 Pfizer Prod Inc 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
PT1874781E (pt) * 2006-04-19 2009-07-27 Boehringer Ingelheim Int Di-hidro-tienopirimidinas para o tratamento de doenças inflamatórias
EP1847543A1 (de) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
BRPI0818006B8 (pt) 2007-10-19 2021-05-25 Boehringer Ingelheim Int compostos de piperidino-di-hidrotienopirimidinas substituídas, uso dos mesmos e formulações farmacêuticas
ATE537175T1 (de) 2007-10-19 2011-12-15 Boehringer Ingelheim Int Neue piperazino-dihydrothienopyrimidin-derivate
WO2009050242A2 (de) 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh Heterocyclus-substituierte piperazino-dihydrothienopyrimidine
CN102007124B (zh) 2008-02-15 2014-06-18 里格尔制药公司 嘧啶-2-胺化合物及其作为jak激酶抑制剂的用途
WO2009111531A1 (en) * 2008-03-06 2009-09-11 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2009124119A2 (en) * 2008-04-01 2009-10-08 The Trustes of Columbia University in the City of New York Phosphodiesterase inhibitors and uses thereof
KR101683042B1 (ko) 2008-04-04 2016-12-06 포사이트 비젼4, 인크. 통증 관리 및 시력을 위한 치료 장치
EP2116618A1 (en) 2008-05-09 2009-11-11 Agency for Science, Technology And Research Diagnosis and treatment of Kawasaki disease
WO2010014930A2 (en) * 2008-08-01 2010-02-04 Biocryst Pharmaceuticals, Inc. Therapeutic agents
CN101747282A (zh) 2008-12-10 2010-06-23 上海特化医药科技有限公司 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途
WO2011050327A1 (en) 2009-10-23 2011-04-28 Forsight Labs Llc Corneal denervation for treatment of ocular pain
WO2011050365A1 (en) 2009-10-23 2011-04-28 Forsight Labs, Llc Conformable therapeutic shield for vision and pain
HUE033019T2 (en) * 2011-05-17 2017-11-28 Principia Biopharma Inc Tyrosine kinase inhibitors
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
US9802954B2 (en) 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
JO3753B1 (ar) 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
JP6310072B2 (ja) 2013-06-26 2018-04-11 ネクシスビジョン， インコーポレイテッド 屈折矯正のためのコンタクトレンズ
WO2015054317A1 (en) * 2013-10-07 2015-04-16 Kadmon Corporation, Llc Rho kinase inhibitors
EA033298B1 (ru) 2015-03-03 2019-09-30 Саниона А/С Комбинированная лекарственная форма тезофензина и метопролола
JP6929286B2 (ja) * 2015-12-18 2021-09-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 治療用化合物、組成物及びその使用方法
WO2018049214A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
WO2018049191A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridone derivatives as hpk1 modulators and uses thereof for the treatment of cancer
KR102507967B1 (ko) 2016-09-09 2023-03-09 인사이트 코포레이션 Hpk1 조절제로서의 피라졸로피리딘 유도체 및 암을 치료하기 위한 이의 용도
WO2018152220A1 (en) 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
CA3063174A1 (en) * 2017-05-12 2018-11-15 Innovus Pharmaceuticals, Inc. Therapeutic methods and compositions
US10722495B2 (en) 2017-09-08 2020-07-28 Incyte Corporation Cyanoindazole compounds and uses thereof
US10864205B2 (en) 2017-12-01 2020-12-15 Innovus Pharmaceuticals, Inc. Nutritional supplement for improving sexual health in men and women
US20190167699A1 (en) 2017-12-01 2019-06-06 Innovus Pharmaceuticals, Inc. Prostate function support formula
US10500199B2 (en) 2017-12-01 2019-12-10 Innovus Pharmaceuticals, Inc. Nutritional supplement for increasing cognitive functions
US10758505B2 (en) 2017-12-01 2020-09-01 Innovus Pharmaceuticals, Inc. Therapeutic compositions and methods
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
US10752635B2 (en) 2018-02-20 2020-08-25 Incyte Corporation Indazole compounds and uses thereof
MX2020008656A (es) 2018-02-20 2020-12-09 Incyte Corp Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores de la cinasa de progenitores hematopoyeticos 1 (hpk1) para tratar el cancer.
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
JP7399968B2 (ja) 2018-09-25 2023-12-18 インサイト・コーポレイション Ａｌｋ２及び／またはｆｇｆｒ調節剤としてのピラゾロ［４，３－ｄ］ピリミジン化合物
CN114450276A (zh) 2019-08-06 2022-05-06 因赛特公司 Hpk1抑制剂的固体形式
AU2021309876A1 (en) * 2020-07-14 2023-02-23 Wuhan Ll Science And Technology Development Co., Ltd. Rock inhibitor, and preparation method therefor and use thereof

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3951980A (en) 1974-05-09 1976-04-20 Stanford Research Institute 3-Substituted-8-methyl-3,8-diazabicyclo[3.2.1]octanes
AU516604B2 (en) 1978-04-03 1981-06-11 Yoshida Kogyo K.K. Tiltable roller assembly
DE3650699T2 (de) 1985-03-15 1999-04-15 Antivirals Inc Immunotestmittel für Polynukleotid und Verfahren
US4666908A (en) 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
US4812590A (en) 1987-06-25 1989-03-14 Merck & Co., Inc. Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma
WO1989000158A1 (en) 1987-07-02 1989-01-12 Pfizer Inc. Bridged-diazabicycloalkyl quinolone carboxylic acids and esters
GB8728483D0 (en) 1987-12-04 1988-01-13 Ciba Geigy Ag Chemical compounds
US5091431A (en) * 1988-02-08 1992-02-25 Schering Corporation Phosphodiesterase inhibitors
US5075310A (en) 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
FR2638745B1 (fr) 1988-11-08 1994-01-14 Synthelabo Derives de ((n-alkylthioalkyl-methylamino)-2 ethyl)-5 benzothiazepine-1,5 one-4, leur preparation et leur application en therapeutique
US4994460A (en) 1989-06-01 1991-02-19 Bristol-Myers Squibb Co. Agents for treatment of brain ischemia
JPH03142277A (ja) 1989-10-30 1991-06-18 Fuji Photo Film Co Ltd 記録材料
US5442044A (en) 1991-01-04 1995-08-15 Pfizer Inc. Orally active renin inhibitors
KR100236808B1 (ko) 1991-07-03 2000-02-01 로렌스 티. 마이젠헬더 에이즈 치료약제로서의 치환된 인돌
GB9119704D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9121028D0 (en) 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
GB9213623D0 (en) 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
JP2657760B2 (ja) 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
GB9218322D0 (en) 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
GB9423911D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
US5869486A (en) 1995-02-24 1999-02-09 Ono Pharmaceutical Co., Ltd. Fused pyrimidines and pyriazines as pharmaceutical compounds
HUP9801394A3 (en) 1995-03-10 2000-07-28 Sanofi Pharmaceuticals Inc New 6-phenyl-pyrazolo[3,4-d]pyrimidin-4-one derivatives and pharmaceutical compositions containing them
US5656629A (en) 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
CZ68199A3 (cs) 1996-08-28 1999-11-17 Pfizer Inc. 6,5-Heterobicyklické deriváty, farmaceutická kompozice na jejich bázi a způsob léčení chorob
DE19644228A1 (de) 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidine
PL336586A1 (en) 1997-04-25 2000-07-03 Pfizer Pyrazoylpyrimidinones inhibiting the cyclic guanosine 3',5'-monophosphate phosphodiesterase of type 5 (cgmp pde5) for treating sexual disorders
US6184338B1 (en) 1997-08-27 2001-02-06 Fmc Corporation Anionic polymerization initiators containing tertiary amine functionality, their chain extended analogues, and processes for using the same
SK287161B6 (sk) 1997-11-12 2010-02-08 Bayer Healthcare Ag 2-Fenylsubstituované imidazotriazinóny, spôsob ich výroby, liečivá obsahujúce tieto látky a ich použitie
DE19752952A1 (de) 1997-11-28 1999-06-02 Merck Patent Gmbh Thienopyrimidine
CA2260499A1 (en) 1998-01-29 1999-07-29 Sumitomo Pharmaceuticals Company Limited Pharmaceutical compositions for the treatment of ischemic brain damage
GB9804426D0 (en) 1998-03-02 1998-04-29 Pfizer Ltd Heterocycles
HUP0102543A3 (en) 1998-04-20 2002-01-28 Pfizer Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction and medicaments containing them
BR9915532A (pt) 1998-10-23 2001-08-14 Pfizer Inibidores de cgmp pde5 de pirazolopirimidinona para tratamento da disfunção sexual
AU3514200A (en) 1999-03-10 2000-09-28 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
US6465486B1 (en) 1999-03-12 2002-10-15 Ortho-Mcneil Pharmaceutical, Inc. Pyridyl/quinolinyl imidazoles
GB9912415D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
DE19942474A1 (de) 1999-09-06 2001-03-15 Merck Patent Gmbh Pyrazolo[4,3-d]pyrimidine
AU7737900A (en) 1999-09-30 2001-04-30 Neurogen Corporation Amino substituted pyrazolo(1,5,-a)-1,5-pyrimidines and pyrazolo(1,5-a)-1,3,5-triazines
EA200200424A1 (ru) 1999-09-30 2002-12-26 Ньюроджен Корпорейшн Некоторые гетероциклы, замещенные алкилендиамином
YU23802A (sh) 1999-09-30 2004-09-03 Neurogen Corporation Određeni alkilen diamin-supstituisani pirazolo/1,5-a/-1,5- piramidini i pirazolo/1,5-a/1,3,5-triazini
EP1222190A1 (en) 1999-10-11 2002-07-17 Pfizer Limited 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
US6548509B2 (en) 1999-10-22 2003-04-15 Neurogen Corporation 3-aryl substituted pyrazolo[4,3-D]pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands
GB9926302D0 (en) 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
GB9930570D0 (en) 1999-12-23 2000-02-16 Pfizer Ltd Therapy
JP2003518485A (ja) 1999-12-23 2003-06-10 ファイザー・プロダクツ・インク 向上された薬物濃度を与える医薬組成物
US20030187261A1 (en) 2000-01-07 2003-10-02 Libor Havlicek Purine derivatives, process for their preparation and use thereof
US20010047013A1 (en) 2000-03-10 2001-11-29 Fengrui Lang Process for the preparation of arylamines
DE10031584A1 (de) 2000-06-29 2002-01-10 Merck Patent Gmbh 5-Aminoalkyl-pyrazolo[4,3-d]pyrimidine
EP1176142A1 (en) 2000-07-28 2002-01-30 Pfizer Inc. Process for the preparation of pyrazoles
EP1176147A1 (en) 2000-07-28 2002-01-30 Pfizer Limited Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-ones and intermediates thereof
EE200300045A (et) 2000-07-28 2004-12-15 Pfizer Inc. Kristalne ravimaine
WO2002013798A2 (en) 2000-08-11 2002-02-21 Pfizer Limited Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors
US6821966B2 (en) 2000-11-20 2004-11-23 Scios, Inc. Inhibitors of p38 kinase
DE10058662A1 (de) 2000-11-25 2002-05-29 Merck Patent Gmbh Verwendung von Pyrazolo[4,3-d]pyrimidinen
JP2004516270A (ja) 2000-12-19 2004-06-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング ピラゾロ〔４，３−ｄ〕ピリミジンおよび抗血栓剤、カルシウム拮抗剤、プロスタグランジンまたはプロスタグランジン誘導体を含む医薬製剤
DE10104095A1 (de) 2001-01-31 2002-08-01 Merck Patent Gmbh Pharmazeutische Formulierung enthaltend Pyrazolo [4,3-d]pyrimidine und Nitrate
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
JP2002255932A (ja) 2001-03-01 2002-09-11 Katayama Seiyakushiyo:Kk ３−アルキルアミノアゼチジンの製造方法
US20020127593A1 (en) 2001-03-12 2002-09-12 Regents Of The University Of California Fluorescence assay for DNA modifying enzymes
GB0106631D0 (en) 2001-03-16 2001-05-09 Pfizer Ltd Pharmaceutically active compounds
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
US6432957B1 (en) 2001-06-29 2002-08-13 Kowa Co., Ltd. Piperazine derivative
JP5420135B2 (ja) 2002-03-15 2014-02-19 ウエイン・ステイト・ユニバーシテイ 抗ウイルス薬としての新規２−アミノ−９−［（２−ヒドロキシメチル）シクロプロピリデンメチル］プリン
DK1348707T3 (da) 2002-03-28 2010-12-13 Ustav Ex Botan Av Cr V V I Inst Of Ex Botany Academy Of Sciences Of The Czech Republic Pro Pyrazolo[4,3-d]pyrimidiner, fremgangsmåder til deres fremstilling samt deres terapeutiske anvendelse
US7505971B2 (en) 2002-06-28 2009-03-17 Hewlett-Packard Development Company, L.P. Shared drive that provides shared access to editable files in a database
WO2004096810A1 (en) 2003-04-29 2004-11-11 Pfizer Limited 5,7-diaminopyrazolo`4,3-d!pyrimidines useful in the treatment of hypertension

Also Published As

Publication number Publication date
NZ542097A (en) 2008-12-24
AR044116A1 (es) 2005-08-24
CA2523831A1 (en) 2004-11-11
AU2004234158A1 (en) 2004-11-11
MA27771A1 (fr) 2006-02-01
IS8009A (is) 2005-08-31
US20050043325A1 (en) 2005-02-24
HK1087108A1 (en) 2006-10-06
EP1620437A1 (en) 2006-02-01
ATE433978T1 (de) 2009-07-15
US7262192B2 (en) 2007-08-28
ES2326119T3 (es) 2009-10-01
CO5640118A2 (es) 2006-05-31
EP1620437B1 (en) 2009-06-17
PE20050462A1 (es) 2005-07-19
PA8601701A1 (es) 2004-11-26
NL1026074C2 (nl) 2005-08-09
WO2004096810A1 (en) 2004-11-11
OA13050A (en) 2006-11-10
JP2007217419A (ja) 2007-08-30
EA008596B1 (ru) 2007-06-29
GEP20084329B (en) 2008-03-25
JP2006524636A (ja) 2006-11-02
JP4015176B2 (ja) 2007-11-28
EA200501333A1 (ru) 2006-06-30
NO333850B1 (no) 2013-09-30
NO20054404D0 (no) 2005-09-22
TWI273908B (en) 2007-02-21
KR100824193B1 (ko) 2008-04-21
AU2004234158B2 (en) 2010-01-28
DE602004021585D1 (de) 2009-07-30
ECSP056130A (es) 2006-03-01
RS20050810A (en) 2007-08-03
CL2004000889A1 (es) 2005-03-18
NL1026074A1 (nl) 2004-11-01
TW200503724A (en) 2005-02-01
UY28290A1 (es) 2004-11-30
CR8051A (es) 2006-08-09
DK1620437T3 (da) 2009-08-24
CA2523831C (en) 2008-11-18
MXPA05011643A (es) 2005-12-15
US20070270412A1 (en) 2007-11-22
KR20060007405A (ko) 2006-01-24
BRPI0409903A (pt) 2006-04-25

Similar Documents

Publication Publication Date Title
NO20054404L (no) 5,7-Diaminopyrazolo [4,3-D] Pyrimidiner Anvendelige ved behandling av of Hypertensjon
NO20062950L (no) 5,7-diaminopyrazolo `43-Dlpyrimidiner med PDE-5 inhiberende aktivitet
NO20071642L (no) N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger
WO2004013120A8 (en) Novel benzodioxoles
DE60214703D1 (de) Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
NO20021379L (no) Benzodiazepin-derivater, fremstilling og anvendelse derav
GB0510143D0 (en) Novel compounds A1
WO2003006425A3 (en) Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
HK1068626A1 (en) Chemical compounds
PL373645A1 (en) Pyrrolidinedione substituted piperidine-phthalazones as pde4 inhibitors
WO2004091514A3 (en) Cgrp receptor antagonists
NO20062256L (no) Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner
BR0209149A (pt) Ftalazinonas
BRPI0509731A (pt) pirazol[4,3-d]pirimidinas
SE0103710D0 (sv) Compounds
RS19504A (en) Novel compounds and compositions as cathepsin inhibitors
MXPA04006041A (es) Antivirales de piridoquinoxalina.
DE60317684D1 (de) SUBSTITUIERTE 2,4-DIHYDROPYRROLOc3,4BÜCHINOLIN-9-ONDERIVATE, DIE SICH ALS PHOSPHODIESTERASEINHIBITOREN EIGNEN
BR0318521A (pt) arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados
DE60213802D1 (de) Cak inhibitoren und deren verwendungen
TNSN05276A1 (fr) 5,7-diaminopyrazolo[4,3-d] pyrimidines utiles dans le traitement de l'hypertension
MXPA04005988A (es) 3,4-dihidro-1h-isoquinolin-2-il-derivados.
ATE365732T1 (de) Pyrimidine als inhibitoren von phosphoinositid-3- kinasen (pi3k)
NO20042729L (no) Heksasykliske forbindelser
AU2003266093A1 (en) Cyclooct-(en-)yl derivatives for use as fragrances

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees